| ¿µ¹® | hearing aid | ÇÑ±Û | º¸Ã»±â |
|---|---|---|---|
| ¼³¸í | ÀÏÁ¾ÀÇ È®¼ºÀåÄ¡·Î¼ ³Ã»À» º¸ÃæÇϱâ À§ÇØ ±Í¿¡ ÀåÂøÇÏ´Â ±â±¸. ¿¾³¯¿¡´Â ³ªÆÈÇüÀÇ ÁýÀ½±â¿´´ø °ÍÀÌ Áö±ÝÀº º¸Åë À½ÀÇ ÁõÆøÀ» µ½´Â Àü±âº¸Ã»±â°¡ ¾²ÀδÙ. ²ÀÁö¿¡ ÀåÂøÇÏ´Â »ÀÀüµµµµ ÀÖÀ¸³ª ´ë°³´Â °ø±âÀü½ÄÀ¸·Î µÈ °ÍÀÌ ¸¹´Ù. Áï, À½ÆÄ¸¦ ¸¶ÀÌÅ©·ÎÆùÀ¸·Î ¹Þ¾Æ Àü±âÁøµ¿À¸·Î ¹Ù²Ù¾î À̰ÍÀ» ÁõÆø±â·Î È®´ëÇÏ¿© À̾îÆùÀ¸·Î ´Ù½Ã À½ÆÄ·Î ¸¸µé¾î ±Í¿¡ µé¸®°Ô ÇÑ´Ù. ³Ã» °¡¿îµ¥¼µµ ÀüÀ½¼º ³Ã»¿¡´Â È¿°ú°¡ ÀÖÀ¸³ª, ½Å°æ°è ±â´ÉÀúÇϰ¡ ¿øÀÎÀÎ ¼Ó±Í¿Í °ü·ÃµÈ °¨À½¼º ³Ã»¿¡´Â º°·Î È¿°ú¸¦ ±â´ëÇÒ ¼ö ¾ø´Ù. º¸Ã»±âÀÇ »ç¿ëÇѰè´Â Àß µé¸®´Â ÂÊ ±ÍÀÇ Æò±Õû·Â¼Õ½Ç 30dB(Á¤»óû·ÂÀÇ 1/30)À» ±âÁØÀ¸·Î ÇÏ¿© À̺¸´Ù °æµµÀÏ ¶§´Â Çʿ䰡 ¾ø°í ±× ÀÌ»óÀÇ Àå¾Ö°¡ ÀÖÀ» ¶§ Àû¿ëµÈ´Ù. º¸Ã»±â´Â Æ®·£Áö½ºÅÍ¿¡¼ IC ȸ·Î·Î ÀüÀÚ±â¼úÀÇ ÁøÀü°ú ÇÔ²² °³·®µÇ¾î °¨µµµµ ÁÁÀ»»Ó´õ·¯ ¾ÆÁÖ ÀÛ¾ÆÁö°í, ÁõÆøÀåÄ¡ºÎ¸¦ ¿©·¯ ÇüÅ·Π¸¸µç °ÍÀÌ ÆÇ¸ÅµÇ°í ÀÖ´Ù. ¿¹¸¦ µé¸é, ¾È°æÅ׿¡ ¼¼Æ®µÇ¾î ÀÖ´Â ¾È°æÇü, ±Í¿¡ °É°Ô µÇ¾î ÀÖ´Â ±ÍµÚÇü, ¿©ÀÚÀÇ ¸Ó¸®ÇÉ ÇüÀ̳ª ³ØÅ¸ÀÌÇÉ Çü, Æ÷ÄÏÇü µîÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | test | ÇÑ±Û | °Ë»ç |
|---|---|---|---|
| ¼³¸í | ¾î¶² ´Ù¸¥ ¹°ÁúÀ» °ËÃâ, ÃøÁ¤, »ý¼ºÇϱâ À§ÇÑ Æ¯Á¤ÇÑ ÈÇйÝÀÀÀ» ÀÏÀ¸Å°´Âµ¥ »ç¿ëµÇ´Â ¹æ¹ý. |
||
| ¿µ¹® | scratch test | ÇÑ±Û | ³Àý¹ý |
|---|---|---|---|
| ¼³¸í | ÇǺθ¦ ³¯Ä«·Î¿î ¹Ù´Ã·Î ±Ü¾î ÇǺÎÀÇ ¹ÝÀÀÀ» º¸´Â °Ë»ç·Î ÇǺΠ°ú¹Î¹ÝÀÀÀ̳ª ¾Ë·¹¸£±â¸¦ ¾Ë¾Æº¸±â À§ÇÑ °Ë»çÀÌ´Ù. ¹Ù´Ã³¡¿¡ Ç׿øÀ» ¹¯Èù µÚ, ÇǺιØÀ» ±Ü¾î ¹ÝÀÀÀ» ¾Ë¾Æº»´Ù. À̶§ Ç׿øÀÌ ¾Æ´Ñ ´ëÁ¶¹°Áú(¿¹¸¦ µé¾î º¸ÅëÀÇ ¹°)À» ¹¯Èù ¹Ù´ÃÀ» °°ÀÌ ¹ÝÀÀÇÏ¿© ÇǺ馱âÁõ(dermographism) ´ÜÁö ¹Ù´ÃÀÇ ±ÜÈû¸¸À¸·Î ¾Ë·¹¸£±â °°Àº ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Çö»ó°ú °¨º°ÇØ¾ß ÇÑ´Ù. ³Ã», û·Â¼Ò½Ç(hearing loss) û°¢ÀÌ ÀúÇÏ ¶Ç´Â »ó½ÇµÈ »óÅÂ. ¿øÀΰú Á¤µµ´Â ¿©·¯ °¡ÁöÀε¥, ³Ã»Àº ±× Á¤µµ°¡ °¡Àå ½ÉÇÑ »óÅÂÀÌ´Ù. û°¢ÀÇ Àüµµ°æ·Î¿¡ Àå¾Ö°¡ ÀÖÀ» ¶§ ³Ã»ÀÌ ÀϾ°í, ±× º´ÅͰ¡ ¿ÜÀ̵µ³ª ÁßÀÌ¿¡ ÀÖ´Â °ÍÀ» ÀüÀ½³Ã», ³»ÀÌ¿¡ ÀÖ´Â °ÍÀ» °¨À½ ³Ã»À̶ó ÇÏ¿© ±¸ºÐÇÑ´Ù. ¶Ç º´ÅÍÀÇ ÀÚ¸®¸¦ ¸í½ÃÇÏ¿© ÁßÀ̼º ³Ã»À̳ª ¹Ì·Î¼º ³Ã» µîÀ¸·Î ¼¼ºÐÇϱ⵵ ÇÑ´Ù. |
||
| ¿µ¹® | stool guaiac test | ÇÑ±Û | ´ëº¯ ±¸¾ÆÀÌ¾Ç °Ë»ç |
|---|---|---|---|
| ¼³¸í | ´ëº¯³»¿¡ ÀÖÀ» ¼ö ÀÖ´Â ÀáÇ÷(´«¿¡ º¸ÀÌÁö ¾Ê´Â ÃâÇ÷)À¯¹«¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, Ç÷±¸³»ÀÇ heme peroxidase¿¡ ÀÇÇØ guaiacÀÌ »êȵǴ ¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÑ´Ù. ¹æ¹ýÀº 3Àϰ£¿¡ °ÉÃÄ ÇÑ º¯¿¡¼ 2±ºµ¥¾¿ äÃëÇÏ¿© °Ë»çÇÑ´Ù. À§¾ç¼º ¹ÝÀÀ(°ÅÁþÀ¸·Î Ç÷¾×ÀÌ ÀÖ´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº ½Ä¹° °ú»êÈÈ¿¼Ò¸¦ ÇÔÀ¯Çϰí ÀÖ´Â È«´ç¹«ÀÇ ¼·Ã볪 Ç÷±¸ ¼ººÐÀ» ÇÔÀ¯Çϰí ÀÖ´Â °í±â ¼·Ãë µî¿¡¼ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, À§À½¼º ¹ÝÀÀ(½ÇÁ¦·Î Ç÷¾×Àº ÀÖÁö¸¸, Ç÷¾×ÀÌ ¾ø´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº ȯ¿ø·ÂÀ» °¡Áö°í ÀÖ´Â ºñŸ¹Î CÀÇ º¹¿ë½Ã ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ƯÈ÷ À§¾ç¼º ¹ÝÀÀÀÌ ¸Å¿ì ÈçÇÏ´Ù. |
||
| ¿µ¹® | Rorschach Test | ÇÑ±Û | ·Î¸£»þÇÏ °Ë»ç |
|---|---|---|---|
| ¼³¸í | »ç°íÀå¾Ö¿Í Á¤¼Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö ãµµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®ÇÏ¸é ±×ÀÇ »ç°í¿Í Á¤¼»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. |
||
| HL | hairline; hairy leukoplakia; half life; hearing level; hearing loss; heparin lock; histiocytic lymph... |
|---|---|
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| BST | bacteriuria screening test; blood serologic test; brief stimulus therapy |
| DEST | Denver Eye Screening Test; dichotic environmental sounds test |
| differential screening | Process in development of a multicellular organism by which cells become specialised for particular functions. Requires that there is selective expression of portions of the genome, the fully differentiated state may be preceded by a stage in which the cell is already programmed for differentiation but is not yet expressing the characteristic phenotype determination. (18 Nov 1997) |
|---|---|
| drug screening | Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. (12 Dec 1998) |
| drug screening assays, antitumour | Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals. (12 Dec 1998) |
| familial screening | Screening directed at close relatives of probands with diseases that may lie latent, as in age-dependent dominant traits, or that may involve risk to progeny, as X-linked traits. (05 Mar 2000) |
| ABO haemolytic disease of the newborn | Erythroblastosis foetalis due to maternal-foetal incompatibility with respect to an antigen of the ABO blood group; the foetus possesses A or B antigen which is lacking in the mother, and the mother produces immune antibody which causes haemolysis of foetal erythrocytes. (05 Mar 2000) |
| bullous impetigo of newborn | Usually, widely disseminated bullous lesions appearing soon after birth, caused by infection with Staphylococcus aureus. Synonym: impetigo neonatorum, pemphigus gangrenosus. (05 Mar 2000) |
| respiratory distress syndrome of the newborn | A disease seen especially in premature neonates with respiratory distress; characterised postmortem by atelectasis and alveolar ducts lined by an eosinophilic membrane; also associated with reduced amounts of lung surfactant. Synonym: hyaline membrane syndrome, respiratory distress syndrome of the newborn. (05 Mar 2000) |
| pleural effusion in newborn | <radiology> Chylothorax most common cause of large effusion, erythroblastosis foetalis, Turner syndrome, congestive heart failure, infantile polycystic kidneys, wet-lung disease, hypervolaemia (idiopathic or iatrogenic), oesophageal tear, enteric cyst, obstructed pulmonary veins (12 Dec 1998) |
| congenital epulis of newborn | A congenital benign nodular tumour of the alveolar ridge, of unknown histogenesis; histologically, it is composed of large cells with a granular cytoplasm similar to that of a granular cell tumour (myoblastoma). (05 Mar 2000) |
| postnatal pit of the newborn | It marks the site where the embryonic spinal cord attaches to the skin. Synonym: postnatal pit of the newborn. (05 Mar 2000) |
| haemolytic anaemia of newborn | <haematology> A condition which develops in the foetus due to an incompatibility between the mother's blood type (RH factor) and the baby's. Maternal antibodies, which enter the foetal circulation during delivery attack the baby's red blood cells leading to haemolysis (rupture of the cells). Symptoms include an infant with an enlarged liver and spleen, swelling, jaundice and anaemia. (27 Sep 1997) |
| haemolytic disease of newborn | <haematology> A condition which develops in the foetus due to an incompatibility between the mother's blood type (RH factor) and the baby's. Maternal antibodies, which enter the foetal circulation during delivery attack the baby's red blood cells leading to haemolysis (rupture of the cells). Symptoms include an infant with an enlarged liver and spleen, swelling, jaundice and anaemia. (27 Sep 1997) |
| haemolytic disease of the newborn | Abnormal breakup of red blood cells in the foetus or newborn. This is usually due to antibodies made by the mother directed against the baby's red cells. It is typically caused by rh incompatibility, that is differences between the mother and baby uinvolving the rh blood group. (12 Dec 1998) |
| haemorrhagic disease of newborn | A self-limited haemorrhagic disorder of the first days of life, caused by a deficiency of the vitamin k-dependent blood coagulation factors II, vii, ix, and x. (12 Dec 1998) |
| haemorrhagic disease of the newborn | A syndrome characterised by spontaneous internal or external bleeding accompanied by hypoprothrombinaemia, slightly decreased platelets, and markedly elevated bleeding and clotting times, usually occurring between the third and sixth days of life and effectively treated with vitamin K. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|